Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Roberts

Physician Assistant Amarillo, TX Physician Assistant

NPI 1235535477 CMS profile 10469093

1901 Medi Park Dr Ste 2058, Amarillo, TX 79106

Open in the dashboard

General payments

$17,025

1,045 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Roberts of Amarillo, TX is reported in the CMS Open Payments database as having received $17,025 across 1,045 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,423 133
2024 General $4,445 284
2023 General $4,579 286
2022 General $3,912 243
2021 General $1,665 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Roberts
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brittany Roberts were reported at $2,423. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brittany Roberts Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,665 $132 $37–$438 $132
2022 $3,912 $155 $48–$522 $149
2023 $4,579 $167 $52–$557 $160
2024 $4,445 $178 $55–$600 $164
2025 $2,423 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Pharmaceuticals, Inc $4,128 219 payments
  2. Neurocrine Biosciences, Inc. $2,125 162 payments
  3. Otsuka America Pharmaceutical, Inc. $1,620 80 payments
  4. Teva Pharmaceuticals USA, Inc. $1,437 128 payments
  5. AbbVie, Inc. $1,379 79 payments
  6. ITI, Inc. $1,365 87 payments
  7. Lundbeck LLC $1,135 58 payments
  8. Axsome Therapeutics, Inc. $1,029 64 payments
  9. Alkermes, Inc. $892 57 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $604 42 payments
  11. Other $1,310 69 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,877 1,043 payments
  2. Education $148 2 payments
Products named General payments · program years 2021–2025
  1. SPRAVATO $2,298 116 payments
  2. INVEGA SUSTENNA $1,843 103 payments
  3. INGREZZA $1,795 140 payments
  4. INVEGA TRINZA $1,639 97 payments
  5. REXULTI Psychiatry $1,479 72 payments
  6. CAPLYTA $1,189 78 payments
  7. VRAYLAR $1,159 69 payments
  8. REXULTI Psychiatry $1,135 58 payments
  9. Auvelity $1,029 64 payments
  10. LYBALVI $781 50 payments
  11. Other $7,327 494 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

4,360

Median for Physician Assistant: 241

Drug cost

$1,265,623

Median for Physician Assistant: $4,110

Branded share of claims

18.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 87 $698,327
Invega Sustenna Paliperidone Palmitate Brand 36 $124,910
Vraylar Cariprazine Hcl Brand 68 $96,704
Austedo Xr Deutetrabenazine Brand 19 $91,583
Rexulti Brexpiprazole Brand 51 $75,952
Caplyta Lumateperone Tosylate Brand 27 $50,106
Latuda Lurasidone Hcl Brand 15 $20,487
Trintellix Vortioxetine Hydrobromide Brand 24 $16,379
Quetiapine Fumarate Generic 262 $8,343
Divalproex Sodium Er Divalproex Sodium Brand 102 $7,832

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$54,259

Medicare's payments for the services billed

Medicare patients

150

Average age 65

Services billed

926

90 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 74%
Arthritis 49%
Diabetes 37%
Ischemic heart disease 28%
Chronic kidney disease 22%
Heart failure 19%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$720 51 —
SPRAVATO
$615 — —
VRAYLAR
$562 68 —
INGREZZA
$472 87 —
CAPLYTA
$286 27 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

1,045 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record